RXi Pharmaceuticals Appoints Peter Campochiaro M.D. to its Scientific Advisory
MARLBOROUGH, Mass., July 7, 2014
MARLBOROUGH, Mass., July 7, 2014 /PRNewswire/ --RXi Pharmaceuticals
Corporation (NASDAQ: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced the appointment
of Dr. Peter Campochiaro to its Scientific Advisory Board. Campochiaro is the
George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience
in the Johns Hopkins University School of Medicine. He is a prominent
researcher, clinician and educator in the field of ophthalmology. He sees
patients at the Wilmer Eye Institute at Johns Hopkins.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
With more than 300 articles published in peer-reviewed medical journals, Dr.
Campochiaro is a clinician-scientist who does both laboratory and clinical
research.His major laboratory interest is in elucidating the molecular
pathogenesis of ocular neovascularization and excessive vascular leakage. He
has generated many animal models of retinal and choroidal vascular diseases
that have been useful for evaluating drug and gene-based therapies. His
laboratory helped to demonstrate the importance of vascular endothelial growth
factor (VEGF) in retinal and choroidal vascular diseases and his clinical
trial group performed many of the early phase studies evaluating VEGF
antagonists. He serves on Scientific Advisory Board of several pharmaceutical
"We are honored to have Dr. Campochiaro join our Scientific Advisory Board,"
said Dr. Pamela Pavco, Chief Development Officer of RXi Pharmaceuticals. "He
brings a wealth of clinical research experience in ophthalmology to the
Company that we will leverage to advance our ophthalmology program."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company
focused on discovering, developing and commercializing innovative therapies
based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform.
Therapeutics that use RNA interference, or "RNAi," have greatpromise because
of their ability to down-regulate the expression of specific genes that may be
over-expressed in disease conditions. Building on the pioneering work of
scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109,
entered into human clinical trials in June 2012 and is currently being
evaluated in Phase 2 clinical trials to reduce dermal scarring (fibrosis).
RXI‑109 targets connective tissue growth factor (CTGF), which may also be key
in the development of retinal scarring.RXi's sd‑rxRNA oligonucleotides are
designed for therapeutic use and have drug-like properties, such as high
potency, target specificity, serum stability, reduced immune response
activation, and efficient cellular uptake. These hybrid oligonucleotide
molecules combine the beneficial properties of conventional RNAi and antisense
technologies. This allows sd‑rxRNAs to achieve efficient cellular uptake and
potent, long-lasting intracellular activity. For more information, please
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks and uncertainties: the risk
that we may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed, risks related
to the development and commercialization of products by our competitors, the
risk related to our ability to control the timing and terms of collaborations
with third parties, and the possibility that other companies or organizations
may assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.
RXi Pharmaceuticals Corporation
SOURCE RXi Pharmaceuticals Corporation
Press spacebar to pause and continue. Press esc to stop.